Cubist Systematic Strategies LLC Invests $2.34 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Cubist Systematic Strategies LLC bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 124,025 shares of the company's stock, valued at approximately $2,337,000. Cubist Systematic Strategies LLC owned about 0.16% of Nurix Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock worth $1,531,000 after acquiring an additional 31,352 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Nurix Therapeutics during the 4th quarter valued at $1,406,000. Barclays PLC lifted its holdings in shares of Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after acquiring an additional 56,190 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after buying an additional 235,971 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in shares of Nurix Therapeutics by 9.3% in the fourth quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company's stock valued at $17,711,000 after buying an additional 79,684 shares in the last quarter.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,198 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at $382,092.92. The trade was a 15.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the transaction, the insider now owns 61,516 shares of the company's stock, valued at $707,434. This represents a 5.20% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,838 shares of company stock worth $221,500. 7.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on NRIX shares. Wells Fargo & Company dropped their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, April 9th. JPMorgan Chase & Co. dropped their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Needham & Company LLC reiterated a "buy" rating and set a $27.00 target price on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Stephens reiterated an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Finally, HC Wainwright reiterated a "buy" rating and set a $36.00 target price on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.44.

Nurix Therapeutics Stock Up 1.1%

Shares of NRIX traded up $0.10 during mid-day trading on Friday, hitting $9.56. The stock had a trading volume of 437,181 shares, compared to its average volume of 878,151. The company has a market cap of $728.82 million, a PE ratio of -3.31 and a beta of 2.23. The company's fifty day simple moving average is $11.07 and its two-hundred day simple moving average is $16.86. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter last year, the firm earned ($0.76) EPS. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.